Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity VITRAFY LIFE SCIENCES LIMITED ABN/ARBN Financial year ended: 48 622 720 254 30 June...
FY26 Appendix 4G
Filed with ASX ·
On 6ix: 6ix.com/news/fy26-appendix-4g-16
6ix hasn’t read this filing yet.
Vitrafy Life Sciences Ltd. on 6ix
In the deck
Story so far
Earlier from Vitrafy Life Sciences
- Vitrafy FY26 Investor Briefing
- Q4 FY26 Quarterly Activities Report and Appendix 4C
- Vitrafy enters a partnership with Hoxworth Blood Center
- Vitrafy Share Purchase Plan Opens - SPP Offer Booklet
- Vitrafy Placement Completion and SPP Announcement
Later from Vitrafy Life Sciences
- FY26 Corporate Governance Statement
- FY26 Appendix 4E and Annual Report
- FY26 Full Year Results Presentation
- Vitrafy enters U.S. Cell & Gene Therapy Market
- S&P DJI Announces September 2026 Quarterly Rebalance
Follow Vitrafy Life Sciences into a list and get an email when it puts out news.
Follow Vitrafy Life Sciences